X4 Pharmaceuticals

About

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

Cambridge,Massachusetts,United States
51 - 100
https://www.x4pharma.com

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $55M
Industries: Biotechnology,Clinical Trials,Health Care,Pharmaceutical,Therapeutics
Founded date: Jan 1, 2014
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: nasdaq:XFOR
Legal Name: X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

8

$239.49M

X4 Pharmaceuticals has raised a total of $239.49M in funding over 2 rounds. Their latest funding was raised on Dec 7, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 7, 2022	Post-IPO Equity	$65M	—	—	—	Detail
Jun 30, 2022	Post-IPO Equity	$55M	7	Acorn Bioventures Lumira Ventures New Enterprise Associates	—	Detail
Mar 19, 2021	Post-IPO Equity	$55M	9	—	—	Detail
Nov 17, 2017	IPO	—	—	—	—	Detail
Nov 16, 2017	Series A	—	1	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

4

0

X4 Pharmaceuticals has made 4 investments. Their most recent investment was on May 3, 2022, when kevin. raised €61.82M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
May 3, 2022 kevin.	Series A	€61.82M	Finance	—
Apr 6, 2021 Mem	Seed	$5.60M	Information Technology	—
Sep 7, 2020 Lokalise	Series A	$6M	Cloud Infrastructure	—
Nov 6, 2019 Digits	Series A	$10.50M	Artificial Intelligence	—

Investors

Number of Lead Investors

Number of Investors

5

17

X4 Pharmaceuticals is funded by 17 investors. Acorn Bioventures and Lumira Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
Acorn Bioventures	Yes	Post-IPO Equity
Lumira Ventures	Yes	Post-IPO Equity
New Enterprise Associates	Yes	Post-IPO Equity
Cormorant Asset Management	Yes	Series B
Hercules Capital	—	Post-IPO Equity
AXA Investment Managers	—	Post-IPO Equity
Bain Capital Life Sciences	—	Post-IPO Equity
OrbiMed	—	Post-IPO Equity
Abingworth	—	Post-IPO Equity
Altium Capital	—	Post-IPO Equity